Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125302832 | 12530283 | 2 | F | 201606 | 20160906 | 20160706 | 20160908 | PER | US-PFIZER INC-2016291536 | PFIZER | 61.00 | YR | F | Y | 96.62000 | KG | 20160908 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125302832 | 12530283 | 1 | PS | CELEBREX | CELECOXIB | 1 | Oral | 200 MG, 1X/DAY | C140333 | 20998 | 200 | MG | CAPSULE, HARD | QD | |||||
| 125302832 | 12530283 | 2 | SS | CELEBREX | CELECOXIB | 1 | 20998 | CAPSULE, HARD | |||||||||||
| 125302832 | 12530283 | 3 | SS | CELEBREX | CELECOXIB | 1 | 20998 | CAPSULE, HARD | |||||||||||
| 125302832 | 12530283 | 4 | SS | CELEBREX | CELECOXIB | 1 | 20998 | CAPSULE, HARD | |||||||||||
| 125302832 | 12530283 | 5 | SS | CELEBREX | CELECOXIB | 1 | 20998 | CAPSULE, HARD | |||||||||||
| 125302832 | 12530283 | 6 | C | HYQVIA | HUMAN IMMUNOGLOBULIN GHYALURONIDASE RECOMBINANT HUMAN | 1 | Intraperitoneal | UNK, WEEKLY | 0 | /wk | |||||||||
| 125302832 | 12530283 | 7 | C | HYQVIA | HUMAN IMMUNOGLOBULIN GHYALURONIDASE RECOMBINANT HUMAN | 1 | Intraperitoneal | UNK, MONTHLY | 0 | /month | |||||||||
| 125302832 | 12530283 | 8 | C | HYQVIA | HUMAN IMMUNOGLOBULIN GHYALURONIDASE RECOMBINANT HUMAN | 1 | UNK | 0 | |||||||||||
| 125302832 | 12530283 | 9 | C | DILTIAZEM. | DILTIAZEM | 1 | 240 MG, 1X/DAY | 0 | 240 | MG | QD | ||||||||
| 125302832 | 12530283 | 10 | C | FLONASE | FLUTICASONE PROPIONATE | 1 | 50 MG, 2X/DAY | 0 | 50 | MG | BID | ||||||||
| 125302832 | 12530283 | 11 | C | GABAPENTIN. | GABAPENTIN | 1 | 300 MG, 3X/DAY | 0 | 300 | MG | TID | ||||||||
| 125302832 | 12530283 | 12 | C | LANTUS | INSULIN GLARGINE | 1 | 30 MG, 1X/DAY (1 X NIGHT) | 0 | 30 | MG | QD | ||||||||
| 125302832 | 12530283 | 13 | C | MELATONIN | MELATONIN | 1 | 5 MG, 1X/DAY (1 X NIGHT) | 0 | 5 | MG | QD | ||||||||
| 125302832 | 12530283 | 14 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | 40 MG, 2X/DAY | 0 | 40 | MG | BID | ||||||||
| 125302832 | 12530283 | 15 | C | POTASSIUM | POTASSIUM | 1 | 10 MG, 1X/DAY | 0 | 10 | MG | QD | ||||||||
| 125302832 | 12530283 | 16 | C | ASPIRIN. | ASPIRIN | 1 | 81 MG, 1X/DAY | 0 | 81 | MG | QD | ||||||||
| 125302832 | 12530283 | 17 | C | ADVAIR HFA | FLUTICASONE PROPIONATESALMETEROL XINAFOATE | 1 | UNK, 2X/DAY (FLUTICASONE PROPIONATE: 250/SALMETEROL XINAFOATE: 50) | 0 | BID | ||||||||||
| 125302832 | 12530283 | 18 | C | METFORMIN | METFORMIN HYDROCHLORIDE | 1 | 1000 MG, 2X/DAY | 0 | 1000 | MG | BID | ||||||||
| 125302832 | 12530283 | 19 | C | PRAVASTATIN. | PRAVASTATIN | 1 | 40 MG, 1X/DAY | 0 | 40 | MG | QD | ||||||||
| 125302832 | 12530283 | 20 | C | LORATADINE. | LORATADINE | 1 | 10 MG, 1X/DAY | 0 | 10 | MG | QD | ||||||||
| 125302832 | 12530283 | 21 | C | TRAZODONE | TRAZODONE HYDROCHLORIDE | 1 | 50 MG, 1X/DAY (1 X NIGHT) | 0 | 50 | MG | QD | ||||||||
| 125302832 | 12530283 | 22 | C | LEVOTHYROXINE. | LEVOTHYROXINE | 1 | 50 MG, 1X/DAY | 0 | 50 | MG | QD | ||||||||
| 125302832 | 12530283 | 23 | C | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | HYDROCHLOROTHIAZIDETRIAMTERENE | 1 | UNK, 1X/DAY (37.5MG: TRIAMTERENE, 25MG: HCTZ) | 0 | QD | ||||||||||
| 125302832 | 12530283 | 24 | C | BUMETANIDE. | BUMETANIDE | 1 | 1 MG, 1X/DAY | 0 | 1 | MG | QD | ||||||||
| 125302832 | 12530283 | 25 | C | VITAMIN B12 | CYANOCOBALAMIN | 1 | 1000 MG, 1X/DAY | 0 | 1000 | MG | QD | ||||||||
| 125302832 | 12530283 | 26 | C | SERTRALINE HCL | SERTRALINE HYDROCHLORIDE | 1 | 50 MG, 1X/DAY | 0 | 50 | MG | QD | ||||||||
| 125302832 | 12530283 | 27 | C | GLIMEPIRIDE. | GLIMEPIRIDE | 1 | 4 MG, 2X/DAY | 0 | 4 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125302832 | 12530283 | 1 | Arthritis |
| 125302832 | 12530283 | 2 | Bursitis |
| 125302832 | 12530283 | 3 | Arthralgia |
| 125302832 | 12530283 | 4 | Back pain |
| 125302832 | 12530283 | 5 | Arthralgia |
| 125302832 | 12530283 | 6 | Immunodeficiency |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125302832 | 12530283 | Arthralgia | |
| 125302832 | 12530283 | Back pain | |
| 125302832 | 12530283 | Fall |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125302832 | 12530283 | 1 | 201606 | 0 | ||
| 125302832 | 12530283 | 6 | 201605 | 0 | ||
| 125302832 | 12530283 | 8 | 201605 | 0 |